Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Pain. 2020 Oct;161(10):2364–2375. doi: 10.1097/j.pain.0000000000001924

Figure 5.

Figure 5.

NR does not interfere with the ability of paclitaxel to suppress the growth of MNU-induced mammary gland tumors in female rats. (A) Survival curves of paclitaxel-treated rats that received concurrent treatment with NR or vehicle (P =0.005). Data are the day tumor burden required euthanasia. (B) Time course of tumor growth. Data from rats that were euthanized before day 26 were not carried forward in the analysis. NR-treated rats (open squares; N=12). Vehicle-treated rats (solid squares, N=12). The open circle depicts the outlier in the vehicle-treated group, which did not respond to paclitaxel with a decrease in tumor growth. * P < 0.05, ** P < 0.01 compared to vehicle-treated group at corresponding time point. † P < 0.05, ‡ P < 0.01 compared to baseline values at day 1 of treatment. (C) Percentage of tumor cells immunoreactive for Ki67. A subset of rats and tumors in each treatment group was selected for analysis. * P < 0.05.